Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia

BACKGROUND: Aripiprazole lauroxil (AL), a long-acting injectable antipsychotic for the treatment of schizophrenia, requires 21 days of oral aripiprazole supplementation upon initiation. We report findings from a phase 1 study investigating a nanocrystalline milled dispersion of AL (AL(NCD)) as a pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Hard, Marjie L., Wehr, Angela Y., Du, Yangchun, Weiden, Peter J., Walling, David, von Moltke, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133194/
https://www.ncbi.nlm.nih.gov/pubmed/30015676
http://dx.doi.org/10.1097/JCP.0000000000000921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133194/
https://www.ncbi.nlm.nih.gov/pubmed/30015676
http://dx.doi.org/10.1097/JCP.0000000000000921

Ejemplares similares